Parvimonas micra can translocate from the subgingival sulcus of the human oral cavity to colorectal adenocarcinoma.
Kelly Conde-PérezElena BuetasPablo Aja-MacayaElsa Martin-De ArribasIago Iglesias-CorrásNoelia Trigo-TasendeMohammed Nasser-AliLara S EstévezSoraya Rumbo-FealBegoña Otero-AlénJose F NogueraÁngel ConchaSimón Pardiñas-LópezMiguel Carda-DiéguezIgor Gómez-RandulfeNieves Martínez-LagoSusana LadraLuis A AparicioGermán BouAlejandro MiraJuan A VallejoMargarita PozaPublished in: Molecular oncology (2023)
Oral and intestinal samples from a cohort of 93 colorectal cancer (CRC) patients and 30 healthy controls (non-CRC) were collected for microbiome analysis. Saliva (28 non-CRC and 94 CRC), feces (30 non-CRC and 97 CRC), subgingival fluid (20 CRC) and tumor tissue samples (20 CRC) were used for 16S metabarcoding and/or RNA sequencing (RNAseq) approaches. A differential analysis of the abundance, performed with the ANCOM-BC package, adjusting the p-values by the Holm-Bonferroni method, revealed that Parvimonas was significantly over-represented in feces from CRC patients (p-value <0.001) compared to healthy controls. A total of 11 Parvimonas micra isolates were obtained from the oral cavity and adenocarcinoma of CRC patients. Genome analysis identified a pair of isolates from the same patient that shared 99.2% identity, demonstrating that P. micra can translocate from the subgingival cavity to the gut. The data suggest that P. micra could migrate in a synergistic consortium with other periodontal bacteria. Metatranscriptomics confirmed that oral bacteria were more active in tumor than in non-neoplastic tissues. We suggest that P. micra could be considered as a CRC biomarker detected in non-invasive samples such as feces.